Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Keros Therapeutics (KROS – Research Report) and keeping the price target at $40.00.
Andrew Fein has given his Buy rating due to a combination of factors surrounding Keros Therapeutics’ promising developments with KER-065. The Phase 1 trial results for KER-065, a novel ligand trap, demonstrated significant multi-system activity with a favorable safety profile, which is crucial for advancing into Phase 2 trials for Duchenne muscular dystrophy (DMD). The drug showed potential in promoting muscle growth, reducing fibrosis and inflammation, and improving metabolic and bone parameters, all of which are critical areas affected in DMD.
Furthermore, KER-065’s unique mechanism is mutation-agnostic, offering systemic benefits that could address the broader neuromuscular disorders market, unlike other treatments that are limited to specific genetic mutations. The observed increases in lean mass and improvements in bone density and fat reduction are particularly noteworthy, as they could significantly impact the quality of life for patients. The company’s plans to initiate a global Phase 2 study and engage with regulators underscore the potential of KER-065 as a first-in-class therapeutic candidate, making it a compelling investment opportunity in an area with significant unmet medical needs.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $41.00 price target.